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Otitis media (OM) (a middle ear infection) is a common childhood illness that can leave some children with permanent hearing
loss. OM can arise following infection with a variety of different pathogens, including a coinfection with influenza A virus (IAV)
and Streptococcus pneumoniae (the pneumococcus). We and others have demonstrated that coinfection with IAV facilitates the
replication of pneumococci in the middle ear. Specifically, we used a mouse model of OM to show that IAV facilitates the out-
growth of S. pneumoniae in the middle ear by inducing middle ear inflammation. Here, we seek to understand how the host in-
flammatory response facilitates bacterial outgrowth in the middle ear. Using B cell-deficient infant mice, we show that antibod-
ies play a crucial role in facilitating pneumococcal replication. We subsequently show that this is due to antibody-dependent
neutrophil extracellular trap (NET) formation in the middle ear, which, instead of clearing the infection, allows the bacteria to
replicate. We further demonstrate the importance of these NETs as a potential therapeutic target through the transtympanic
administration of a DNase, which effectively reduces the bacterial load in the middle ear. Taken together, these data provide
novel insight into how pneumococci are able to replicate in the middle ear cavity and induce disease.
Otitis media (OM) is one of the most common pediatric dis-eases worldwide. It can affect up to 80% of children before
the age of 3 years and can lead to permanent hearing loss (1).Up to
70% of cases of acute OM are caused by viral-bacterial coinfec-
tions (2). Of particular relevance are coinfections with influenza A
virus (IAV) and the bacterium Streptococcus pneumoniae. In clin-
ical cases and experimental models, infection with IAV facilitates
the replication of S. pneumoniae in the middle ear (3–8). Using an
infant mouse model of OM (designed to mimic the underdevel-
oped immune system of children), we have previously demon-
strated that the development of pneumococcal OM in coinfected
mice was due to the inflammation induced by IAV in the middle
ear (3, 8). However, themechanisms by which the host inflamma-
tory response mediates secondary pneumococcal OM remain un-
defined.
Themiddle ear has few resident leukocytes, and an infection in
the organ results in an influx of neutrophils, macrophages, and
lymphocytes (9–11). Neutrophils have traditionally been consid-
ered to play a protective role in OM (12, 13). However, recent
studies have speculated that neutrophils may contribute to bacte-
rial persistence in the middle ear via the formation of neutrophil
extracellular traps (NETs) (14–16). The term NETs refers to the
extracellular DNA produced by neutrophils to “trap” bacterial
pathogens. This extracellular DNA is studded with histones and
antimicrobial compounds to kill the trapped bacteria (17). Inter-
estingly, the pneumococcal capsule and D-alanine residues on
pneumococcal lipoteichoic acids can inhibit NET killing (18), po-
tentially enabling the pneumococcus to survive and persist within
biofilm-like NET structures in the middle ear.
Pneumococcal OM predominately develops in the absence of
preexisting immunity, with incidence peaking between 6 months
(whenmaternal antibodies havewaned) and 2 years, when specific
immunity develops (19). In these immunologically naive individ-
uals, natural antibodies may represent an important defense
mechanism against influenza virus-mediated pneumococcal dis-
ease, as is seen in pneumococcal sepsis (20). Conversely, the for-
mation of immune complexes in the middle ear may facilitate,
rather than clear, bacterial OM (21), suggesting that organ-spe-
cific differences may exist with regard to the role of antibodies
during pneumococcal disease. Moreover, the ability of antibodies
to interact with neutrophils in the middle ear (19), and the sug-
gestion that neutrophils may facilitate bacterial OM (14, 15), may
indicate that the role of antibodies and neutrophils in pneumo-
coccal-influenza virus OM is more complex than simply protect-
ing against disease development.
Here, we use B6.MT/ mice (which lack B lymphocytes)
(22) to investigate the role of antibodies in pneumococcal-influ-
enza virus OM. Our data suggest that antibodies facilitate the de-
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velopment of secondary bacterial OM by inducing NETs in the
middle ear. These NETs, instead of clearing the pneumococci,
may then provide scaffolding for bacterial outgrowth. Accord-
ingly, DNase treatment reduced pneumococcal OM. These data
provide newmechanistic insight into pneumococcal-IAV coinfec-
tions and identify NETs as an important target for treating and
preventing pneumococcal OM.
MATERIALS AND METHODS
Viral and bacterial strains. The bioluminescent S. pneumoniae strain
EF3030lux (type 19F) (23) was used in all experiments. Influenza virus
strain A/Udorn/307/72 (H3N2) was used to model infection with IAV.
Virus stocks were prepared in embryonated eggs and quantified as de-
scribed previously (24).
Mice.Animal experiments were approved by the Animal Ethics Com-
mittee of the University of Melbourne and were conducted in accordance
with the relevant Australian legislation. C57BL/6, B6.MT/, and
B6.pIgR/ mice were bred and housed under specific-pathogen-free
(SPF) conditions at the Department of Microbiology and Immunology,
the University of Melbourne. B6.MT/ mice lack B lymphocytes and
antibodies (although these mice can selectively produce some antibodies)
(22, 25, 26). In contrast, B6.pIgR/mice are deficient in the polymeric Ig
receptor (pIgR) (27, 28). Accordingly, these mice are unable to secrete
polymeric antibodies, and the sera of the mice contain significantly more
IgA and IgG than sera from C57BL/6 (B6) mice (27, 28).
Infection of mice. Five-day old B6 and B6.MT/ mice were colo-
nized intranasally (i.n.) with 2 103 CFU of S. pneumoniae EF3030Lux or
phosphate-buffered saline (PBS) in 3 microliters. At 14 days of age, the
mice were infected intranasally with 102.5 PFU of egg-grown IAV in 3
microliters. Six days post-IAV infection, the mice were euthanized, and
organs were collected for analysis.
Enumeration of bacterial and viral loads. Tissues used to quantify
bacterial and viral loads were collected and processed as described previ-
ously (3, 23). The viral load was determined using plaque assays on
MDCK cells, as described elsewhere (24).
Histology and immunofluorescence.Middle ears were collected and
processed for histological analysis essentially as described previously (3).
Antigen retrieval was performed by heating slides in citrate buffer (anti-
gen retrieval solution; Dako) in amicrowave. The slides were treated with
Image-iT FX Signal Enhancer (Invitrogen), as recommended by theman-
ufacturer, and stained with rabbit anti-CRAMP, a marker for mouse
NETs (7.75 g/ml; provided by Richard Gallo, UCSD, San Diego, CA
[29]) or the respective isotype controls (rabbit IgG whole molecule; Jack-
son ImmunoResearch). The slides were subsequently stained with an
Alexa 647-conjugated goat anti-rabbit antibody (Invitrogen) and mounted
using Prolong Gold with 4=,6=-diamidino-2-phenylindole (DAPI) (Invit-
rogen). For each sample (individual ear), a minimum of three randomly
selected images were acquired (Leica DMI6000CS confocal microscope)
and used for quantification of NET-producing cells. The data were ex-
pressed as percentages of NET-forming cells in relation to the total num-
ber of cells. The mean value derived from random images per sample was
used for statistical analysis.
Antibody transfer.One hundredmicroliters of serawas transferred to
B6.MT/mice (14 to 19 days old) daily via intraperitoneal (i.p.) injec-
tion. Sera used for transfer experiments were collected from naive
B6.pIgR/ mice (male and female) that were 6 weeks of age and
pooled.
Transtympanic injection. IgA was enriched from naive B6.pIgR/
sera using ammonium sulfate immunoprecipitation. IgG was then de-
pleted with protein G (Genscript, USA), and IgA was further purified
using mouse IgA purification resin (Affiland SA, Belgium) according to
themanufacturer’s instructions. IgA purity was confirmed by SDS-PAGE,
Western immunoblotting, and enzyme-linked immunosorbent assay
(ELISA) (data not shown). Purified IgA (2 g) or PBS was then injected
transtympanically into the middle ears of S. pneumoniae EF3030lux-colo-
nized B6.MTmice 4 and 5 days post-IAV infection. Alternatively, 10g
of DNase (Sigma, USA) or PBS was injected transtympanically into the
middle ears of coinfected B6 mice 4 and 5 days post-IAV infection.
ELISA.Total IgA, IgM, and IgG in serum samples and clarifiedmiddle
ear homogenates were measured by a standard ELISA (22). Briefly, 96-
well MaxiSorp immunoplates (Nunc, USA) were coated with goat anti-
mouse IgA, goat anti-mouse IgM, or goat anti-mouse IgG (Sigma). Wells
were blocked with bovine serum albumin (BSA) and washed, and then
serum or middle ear homogenates were added. To generate a standard
curve, serial dilutions of known amounts of purified mouse IgA (BD
Pharmingen, USA), mouse IgM (Millipore, USA), or mouse IgG (AbD
Serotech, United Kingdom) were included on each plate. Following incu-
bation and washing, goat anti-mouse IgA/IgM/IgG horseradish peroxi-
dase-conjugated antibodies (Southern Biotech, USA) were added. Bound
antibody was visualized using an o-phenylenediamine (OPD) substrate,
absorbance was measured at 492 nm in a Multiskan plate reader (Labsys-
tems, Finland), and antibody concentrations were determined using the
relevant standard curve.
RESULTS
B6.MT/mice display reduced pneumococcal outgrowth in
themiddle ear. To assess the role of antibodies in pneumococcal-
influenza virus OM, B6.MT/ mice and B6 mice were colo-
nized with S. pneumoniae. Nine days later, the mice were infected
with IAV, and 6 days later, OMwasmonitored. Six days post-IAV
infection was selected as the time point of interest, as we had
previously assessed the kinetics of the infection and had shown
that day 6 represents the peak of pneumococcal OM in infant B6
mice (3). Consistent with our previous findings (3), B6 mice had
high bacterial titers in themiddle ear following IAV infection (Fig.
1A), which we had previously shown to result in a 20-dB hearing
loss (3). Strikingly, B6.MT/mice displayed significantly lower
pneumococcal titers in themiddle ear than B6mice (Fig. 1A). The
titers of pneumococci in the middle ears of B6.MT/ mice
(approximately 103 CFU) are consistent with bacterial titers in the
middle ears of mice infected with S. pneumoniae alone (3, 8), and
we have demonstrated that this amount of bacteria in the ears does
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FIG 1 Coinfected B6.MT/mice do not display pneumococcal outgrowth
in the middle ear. (A) Titers of S. pneumoniae EF3030lux in the middle ears of
mice 6 days after i.n. infection with IAV. Each data point represents an indi-
vidual ear from one mouse. Statistical significance was determined using a
Mann-Whitney U test and is denoted by three asterisks (P 0.001). The data
are pooled from aminimumof two independent experiments. The dashed line
indicates the detection limit of the assay. (B) Titers of S. pneumoniae EF3030lux
in the nasal cavities of mice 6 days after i.n. infection with IAV. Statistical
significance was determined using a Mann-Whitney U test. The data are
pooled from two independent experiments. The dashed line indicates the de-
tection limit of the assay. Solid lines represent the geometricmean of the assay.
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not result in hearing loss (3). The difference in bacterial outgrowth
between B6 and B6.MT/mice was not due to impaired repli-
cation of IAV in B6.MT/ mice or a reduced inflammatory
infiltrate in the ears of B6.MT/ mice (see Fig. S1 in the sup-
plemental material). Importantly, the observed decrease in pneu-
mococcal replication was restricted to themiddle ear, as no differ-
ences in pneumococcal titers were observed between B6 and
B6.MT/mice in the nasopharynx (Fig. 1B).
Antibodies facilitate pneumococcal outgrowth in themiddle
ear. B6.MT/ mice lack B lymphocytes and therefore, for the
most part, do not produce antibodies (22). However, these mice
can produce at least some level of IgA in response to Salmonella
(25), as well as IgE/IgG in the lung in response to Aspergillus fu-
migatus (26). Therefore, to determine if antibodies could restore
pneumococcal growth, we adoptively transferred serum into
B6.MT/ recipient mice from naive B6.pIgR/ mice (Fig.
2A). B6.pIgR/mice were used instead of wild-type B6 mice, as
they have higher levels of serum IgG and IgA than wild-type mice
(27, 28), thereby reducing the number of intraperitoneal injec-
tions required. Sera were derived from naive mice, rather than
from mice with specific anti-pneumococcal antibodies, as we
found that 20-day-old coinfected mice have not yet developed
significant levels of specific anti-pneumococcal antibodies in the
middle ear (see Fig. S2 in the supplemental material). Therefore,
any putative role of antibodies in pneumococcal OM is not likely
to be driven by specific anti-pneumococcal antibodies. The trans-
fer of naive serum to coinfected B6.MT/ mice significantly
increased bacterial titers in the middle ear relative to mice treated
with PBS (Fig. 2A). Serum transfer also resulted in middle ear
antibody titers that were equivalent to those of coinfected B6mice
(Fig. 2B to D). To confirm that antibodies facilitated pneumococ-
cal outgrowth in the middle ear, we injected IgA purified from
naive sera directly into the middle ears of coinfected B6.MT/
mice. Although we were unable to use a large number of mice for
these experiments, due to the difficulties associated with admin-
istering transtympanic injections to infant mice, the administra-
tion of IgA resulted in higher bacterial and IgA titers than the
injection of PBS (Fig. 2E and F). No reactivity was observed be-
tween the IgA used for these transtympanic injections and pneu-
mococcal or IAV antigens (see Fig. S3A and B in the supplemental
material), suggesting that OM can occur in the absence of specific
anti-pneumococcal/IAV antibodies.
NETs facilitate pneumococcal outgrowth in the ears of coin-
fected B6 mice. We had previously demonstrated that infection
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FIG 2 Transfer of sera induces pneumococcalOM inB6.MT/mice. (A) Titers of S. pneumoniaeEF3030lux in themiddle ears of B6.MT/mice 6 days after
i.n. infection with IAV. The mice were treated by daily i.p. injection at 14 to 19 days of age with sera from adult B6.pIgR/ mice or PBS. Each data point
represents an individual ear from one mouse. Statistical significance (Mann-Whitney U test; P 0.05) is denoted by one asterisk. The data are pooled from a
minimum of two independent experiments. The dashed line indicates the detection limit of the assay. Solid lines represent the geometric mean of the assay. (B
to D) Middle ear antibody titers of IgM (B), IgG (C), and IgA (D) in coinfected 20-day-old B6.MT/ mice following transfer of sera/PBS or in coinfected
20-day-old wild-type B6 mice. Statistical significance was determined using a Kruskal-Wallis test with Dunn’s multiple-comparison test and is denoted by one
asterisk (P 0.05) or three asterisks (P 0.001). The data shown represent the means and standard errors of the mean (SEM) and are pooled from aminimum
of two independent experiments. (E) Titers of S. pneumoniae EF3030lux in themiddle ears of B6.MT/mice 6 days after i.n. infectionwith IAV. Themice were
injected transtympanically with IgA or PBS at 18 and 19 days of age. Each data point represents an individual ear from one mouse. Statistical significance was
determined using a Mann-Whitney U test and is denoted by two asterisks (P  0.01). The dashed line indicates the detection limit of the assay. Solid lines
represent the geometric mean of the assay. (F) Antibody titers in the middle ear homogenates of coinfected B6.MT/mice 6 days after i.n. infection with IAV
and transtympanic injection with either IgA or PBS at 18 and 19 days of age. Statistical significance was determined using aMann-WhitneyU test and is denoted
by one asterisk (P 0.05). The data shown represent the means and SEM.
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with IAV induces an influx of neutrophils into the middle ear
cavities of infant mice (3). Moreover, pneumococci in the ear
colocalize with this influx of neutrophils (3), and neutrophils are
thought to interact with antibodies in the middle ear (19). In light
of the suggested role of NETs in OM (14, 15), we reasoned that
antibodies in the middle ear may facilitate bacterial outgrowth by
inducing NETs. To test this hypothesis, B6 and B6.MT/mice
were coinfected with S. pneumoniae, and IAV andNET formation
in the middle ear was assessed. Immunofluorescence showed that
B6.MT/mice formed significantly fewer NETs in the middle
ear than coinfected wild-type B6 mice (Fig. 3A and B). We con-
firmed with immunofluorescence assays that pneumococci local-
ized to the neutrophilic infiltrate in the middle ears of NET-posi-
tive B6 mice (see Fig. S4 in the supplemental material). The
production ofNETs in themiddle ear was independent of S. pneu-
moniae, as NETs were also detected in the middle ears of B6 mice
infected with IAV alone (Fig. 3A and B).
To confirm that reduced NET formation in B6.MT/mice
was due to the absence of antibodies in the mice, NET formation
was assessed in coinfected B6.MT/mice following transtym-
panic injection of IgA or PBS. The administration of IgA resulted
in a significant increase inNETproduction in themiddle ear com-
pared to injections with PBS (Fig. 3C). PBS-treated B6.MT/
mice displayed reducedNET formation compared to B6.MT/
mice that were not treated transtympanically (Fig. 3B and C),
suggesting that the transtympanic injection itself may limit the
detection of NETs by immunofluorescence. Nevertheless, the sig-
nificant increase in NETs observed in IgA-treated mice relative to
PBS-treated mice suggests that antibodies can facilitate NET pro-
duction in the middle ear.
Due to the sequestered nature of the middle ear, depletion of
neutrophils using the 1A8monoclonal antibody is ineffectual (8).
Instead, to investigate whether the antibody-dependent difference
in NET production observed between B6 and B6.MT/ mice
affected bacterial titers in the middle ear, B6 mice were coinfected
with S. pneumoniae EF3030lux and IAV. DNase was then injected
transtympanically in order to destroy the NETs present in the
middle ear. Alternatively, control mice were treated with PBS.
Bacterial titers in the middle ear were then determined 6 days
post-IAV infection. Treatment with DNase resulted in signifi-
cantly fewer pneumococci in the middle ear than PBS treatment
(Fig. 3D). These data thus suggest that the decreasedNETproduc-
tion in B6.MT/ mice may help reduce pneumococcal out-
growth in the middle ear.
DISCUSSION
OM represents a major health care burden worldwide and can
arise from coinfection with IAV and S. pneumoniae. We have pre-
viously shown that IAV facilitates pneumococcal outgrowth in the
middle ear by triggeringmiddle ear inflammation (3, 8). The pres-
ent study suggests that the ability of antibodies to trigger NET
production in the middle ear may be a key component of the host
inflammatory response that facilitates the development of bacte-
rial middle ear disease.
It has previously been suggested that NETs may be an impor-
tant mechanism by which pneumococci persist in the middle ear
(14, 16), as they are able to reside in NETs and resist NET-medi-
ated killing (18, 30). Consistentwith this notion, bacterial biofilms
entangledwithDNA strands fromNETs can be found in the in the
middle ear effusions of children with recurrent acute OM (16).
Accordingly, it has been suggested that DNases may be a useful
adjunct treatment in children with recurrent or chronic otitis me-
dia (16). However, the therapeutic benefit of DNase treatment in
an animal model of OM has yet to be demonstrated. Here, we
show that not only do coinfectedmice developNETs in themiddle
ear, but the transtympanic administration of a DNase reduces
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FIG 3 NETs facilitate pneumococcal outgrowth in the middle ear. (A) Rep-
resentative immunofluorescence images of neutrophils in the middle ears of
infected 20-day-old B6 or B6.MT/mice. Sections were stained with DAPI
(blue) and anti-CRAMP (red). The insets represent the components of the
image in dashed boxes shown at a highermagnification. SP, S. pneumoniae. (B)
Quantification of NETs in the middle ears of 20-day-old B6 or B6.MT/
mice. For each sample, a minimum of three randomly selected images were
acquired and used to quantify NET-producing cells. The data are expressed as
percentages of NET-forming cells in relation to the total number of cells. The
mean value derived from random images per sample (individual ear) was used
for statistical analysis. Statistical significance was determined using a Mann-
WhitneyU test and is denoted by one asterisk (P 0.05) or two asterisks (P
0.01). The data represent means and SEM. (C) Quantification of NETs in the
middle ears of 20-day-old coinfected B6.MT/ mice following transtym-
panic injection with IgA or PBS. For each sample, a minimum of three ran-
domly selected images were acquired and used to quantify NET-producing
cells. The data are expressed as percentages of NET-forming cells in relation to
the total number of cells. The mean value derived from random images per
sample (individual ear) was used for statistical analysis. Statistical significance
was determined using a Mann-Whitney U test and is denoted by one asterisk
(P  0.05). The data represent means and SEM. (D) Titers of S. pneumoniae
EF3030lux in the middle ears of B6 mice 6 days after i.n. infection with IAV.
Mice were transtympanically injected with DNase or PBS at 18 and 19 days of
age. Each data point represents an individual ear from one mouse. Statistical
significance was determined using a Mann-Whitney U test and is denoted by
two asterisks (P  0.01). The data are representative of two independent
experiments.
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pneumococcal outgrowth in the middle ears of IAV-infected
mice. DNases have previously been used very successfully to treat
patients with cystic fibrosis (31–33). Similarly, a study from the
early 1960s showed that a DNase derived frombeef pancreas had a
therapeutic effect on patients with OM (34). Our data may thus
suggest that DNase treatment could be an efficacious treatment
option for children with OM. Indeed, the ability of a DNase (dor-
nase alpha) to resolve OM in children is currently the subject of a
clinical trial in Australia, where dornase alpha is administered to
the middle ears of children undergoing surgery for grommet in-
sertion (35). In the present study, the transtympanic administra-
tion of DNase to the middle ear was designed to mimic this surgi-
cal administration DNase. Of course, an animal model can never
fully recapitulate the complexity of human disease, and it remains
possible that DNase treatment would not reduce bacterial titers in
children or that this would not result in a subsequent improve-
ment in hearing. Nevertheless, our data suggest that the therapeu-
tic benefits of DNase treatment in OM is an interesting area for
further study.
Surprisingly, we identified antibodies as an important trigger
for NET production in the middle ear. Previous studies have sug-
gested that B6.MT/ mice can at least produce IgE and IgG
upon challenge with a fungal pathogen (26). However, the poten-
tial production of IgE/IgG in these mice followingmicrobial chal-
lenge (26) does not detract from our findings that antibodies me-
diateNET formation and pneumococcal OM.We showed that the
transfer of purified IgA to B6.MT/ mice induced NET pro-
duction in the middle ear, which clearly indicates that antibodies
contribute to disease development. One possible explanation to
reconcile our findings with the suggestion that B6.MT/mice
still produce some antibodies upon infection (26) may be that a
certain threshold level of antibodies is required for the develop-
ment of secondary pneumococcal OM. Alternatively, it is possible
that the CD19CD9 IgDB-1 cells found byGhosh et al. (26) in
the lungs of MT/mice are not present in the middle ear.
A variety of different stimuli have been identified as triggering
NET formation either in vivo or in vitro (36). They include inter-
leukin 8 (IL-8), components of the complement cascade, and se-
lect bacterial and fungal pathogens (36). It is therefore interesting
to consider the ways in which antibodies may trigger NET forma-
tion in themiddle ear. Antibodies could induce NET formation in
an indirect manner by activating the complement cascade (36,
37). The chemotactic complement-derived peptide complement
factor 5a (C5a) can then induce NET formation by neutrophils
that have been primed with granulocyte-macrophage colony-
stimulating factor or interferons (36). While IAV can trigger the
expression of interferon-regulated genes in the middle ear (8), a
role for complement inmiddle ear NET production and pneumo-
coccal OM is inconsistent with previous reports that complement
protects against the development of pneumococcal OM (38).
Moreover, we have found that, in vitro, IgA is able to induce both
NET formation and pneumococcal outgrowth in the absence of
complement (data not shown). Thus, clearly elucidating the path-
way by which antibodies induce NET formation in the middle ear
remains an important area for future studies.
In this study, we used purified IgA to confirm the role of anti-
bodies in NETs and pneumococcal outgrowth in the middle ear.
However, other antibody isotypes may also be able to induce NET
formation in vivo. Indeed, our preliminary data suggest that the
presence of IgG (in the absence of IgA) in the middle ears of
coinfected B6.MT/ mice is also sufficient to facilitate pneu-
mococcal outgrowth (data not shown). Thus, the interactions be-
tween antibodies and NET-producing neutrophils may not be re-
stricted to one antibody isotype.
The antibodies involved in the development ofOM in the pres-
ent study were unlikely to be specific for S. pneumoniae or IAV, as
middle ear disease could be induced in B6.MT/ mice by the
transfer of IgA, which did not bind to pneumococcal or IAV an-
tigens. Moreover, coinfected B6 mice (which develop pneumo-
coccal OM) did not possess pneumococcus-specific antibodies in
themiddle ear. It currently remains unclear if the “OM-inducing”
antibodies observed in this study were natural antibodies (i.e.,
polyspecific, low-affinity antibodies that can be produced in the
absence of apparent antigenic stimuli) (39) or high-affinity anti-
bodies that were produced in response to nonpneumococcal an-
tigens. The possibility also exists that these antibodies actually
bind to self-antigens, as autoantibodies are known inducers of
NET production (40).
It is important to note that despite the findings of this study,
specific anti-pneumococcal antibodies are still likely to protect
against pneumococcal OM, as has been observed in clinical trials
of anti-pneumococcal conjugate vaccines (41, 42). This is due, in
part, to the ability of anti-capsular antibodies to reduce nasopha-
ryngeal colonization with the corresponding serotype strains (43,
44). Colonization is the essential first step in the development of
pneumococcal OM, and an increased number of pneumococci in
the nose is associatedwith an increased risk ofOM(45, 46). There-
fore, regardless of whether anti-pneumococcal antibodies are able
to induce NETS in the middle ear, anti-pneumococcal antibodies
are still likely to decrease the risk of OM by reducing pneumococ-
cal colonization in the nasopharynx.
Finally, this study found that the role of “OM-inducing anti-
bodies” in pneumococcal outgrowth was at least to some extent
tissue specific, as B6.MT/mice did not display reduced pneu-
mococcal titers in the nasal cavity relative to wild-type B6 mice.
However, the role of NETS in secondary pneumococcal disease
may not be restricted to the middle ear. It has recently been dem-
onstrated that mice coinfected with S. pneumoniae and influenza
virus display increased pulmonary lesions and NET formation in
the lung compared to mice infected with either pathogen alone,
and these NETs were unable to kill S. pneumoniae (30). Therefore,
determining the role of NETs, and the stimuli required for their
production, in the pathogenesis of invasive pneumococcal disease
(i.e., pneumococcal pneumonia, sepsis, andmeningitis) remains a
key area for further study.
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